Alirocumab Treatment and Achievement of Non‐High‐Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials

BACKGROUND: Non‐high‐density lipoprotein cholesterol (non‐HDL‐C) and apolipoprotein (apo) B are better predictors of atherosclerotic cardiovascular disease risk than low‐density lipoprotein cholesterol alone. US and European lipid management guidelines support non‐HDL‐C and apoB as targets for lipid...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Am Heart Assoc
Autores principales: Bays, Harold E., Leiter, Lawrence A., Colhoun, Helen M., Thompson, Desmond, Bessac, Laurence, Pordy, Robert, Toth, Peter P.
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5586424/
https://ncbi.nlm.nih.gov/pubmed/28862926
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.117.005639
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares